Patent · US Active

GIP/GLP1 co-agonist compounds

US11084861B2 · kind B2 · utility

3Cited by

2References

10Claims

0Family size

Assignee

ELI LILLY AND COMPANY · US

Inventors

Milata Mary Abraham · Indianapolis, US
Jorge Alsina-Fernandez · Indianapolis, US
Robert Brown · Carmel, US
Over Cabrera · Carmel, US
Tamer Coskun · San Jose, US
Robert Chadwick Cummins · Carmel, US
Mohamed ElSayed Hamed Elsayed · Fishers, US
Hongchang Qu · Carmel, US
James Lincoln Wallis · Woodland, US
Amita Datta-Mannan · Indianapolis, US
Xianyin Lai · Carmel, US

Key dates

Filing date	Jul 22, 2019
Grant date	Aug 10, 2021
Priority date	—
Expiry date	Jul 22, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/0053
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.